menu
    • menu
    [{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Shanghai Healthcare Capital"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"3B Future Health Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ 3B Future Health Fund","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ 3B Future Health Fund"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Sante Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Sante Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Sante Ventures"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Geneos Therapeutics

    Menu

    Geneos Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Cancer Vaccine Trial

    Details : GNOS-PV02 combines DNA plasmid PTCV, IL-12, and pembrolizumab for advanced hepatocellular carcinoma after multi-tyrosine kinase treatment.

    Product Name : GNOS-PV02

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    July 04, 2024

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : 3B Future Health Fund

    Deal Size : $5.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Geneos Therapeutics Secures $5 Million in Series A3 Financing

    Details : The net proceeds will fund expansion of Phase 1b/2a GT-30 Program. GT-30 is evaluating safety, immunogenicity, and efficacy of PTCV (GNOS-PV02 plus plasmid-encoded IL-12) in patients with unresectable or metastatic HCC.

    Product Name : GNOS-PV02

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    December 04, 2023

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : 3B Future Health Fund

    Deal Size : $5.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Shanghai Healthcare Capital

    Deal Size : $10.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Geneos Therapeutics Closes its Series A3 Financing with Investment of $5 Million

    Details : The net proceeds will fund completion of phase 1b/2a GT-30 Program evaluating personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with Pembrolizumab (MK-3475) in subjects with advanced hepatocellular carcin...

    Product Name : GNOS-PV02

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    September 27, 2023

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Shanghai Healthcare Capital

    Deal Size : $10.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Sante Ventures

    Deal Size : $17.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Pl...

    Details : The proceeds will be used for the expansion of the company’s GT-30 Phase Ib/IIa clinical trial. GT-30 evaluates Geneos’ personalized cancer vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer...

    Product Name : GNOS-PV02

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    March 24, 2022

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Sante Ventures

    Deal Size : $17.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed

    Geneos Therapeutics

    U.S.A arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular...

    Details : Geneos Therapeutics' personalized neoantigen-targeting vaccine, GNOS-PV02, will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).

    Product Name : GNOS-PV02

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    January 29, 2020

    Lead Product(s) : GNOS-PV02,INO-9012

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth